TAS 3681

Drug Profile

TAS 3681

Alternative Names: TAS3681

Latest Information Update: 16 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Taiho Pharmaceutical
  • Class Antineoplastics
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 16 Dec 2016 Biomarkers information updated
  • 01 Mar 2016 Phase-I clinical trials in Prostate cancer (Hormone refractory, Second-line therapy or greater, Metastatic disease) in USA (PO) after March 2016 (NCT02566772)
  • 01 Mar 2016 Phase-I clinical trials in Prostate cancer (Metastatic disease, Second-line therapy or greater, Hormone refractory) in United Kingdom (PO) (NCT02566772)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top